Modulation of Immune Signaling and Metabolism Highlights Host and Fungal Transcriptional Responses in Mouse Models of Invasive Pulmonary Aspergillosis

Shiv D. Kale^{1*}, Tariq Ayubi¹, Dawoon Chung^{2,5}, Nuria Tubau-Juni¹, Andrew Leber¹, Ha X. Dang^{1,3}, Saikumar Karyala¹, Raquel Hontecillas¹, Christopher B. Lawrence⁴, Robert A. Cramer², Josep Bassaganya-Riera¹

¹Nutrional Immunology and Molecular Medicine Laboratory, Biocomplexity Institute of Virginia Tech. Blacksburg, VA 24061 USA

²Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755 USA

³Current Address: McDonnell Genome Institute at Washington University, St. Louis, MO 63108 ⁴Department of Biological Sciences, Virginia Tech. Blacksburg, VA 24061 USA

⁵Current Address: National Marine Biodiversity Institute of Korea, Seochun-gun, 33662, Republic of Korea

Corresponding Author *: Shiv D. Kale (sdkale@vt.edu)



Supplementary Figure S1. Measurement of *A. fumigatus* 18s rRNA during chemotherapeutic and steroid models of invasive pulmonary aspergillosis on day 2 and 3 post inoculation. (A) RT-qPCR based fold change of 18s rRNA normalized to host β -actin mRNA, and then further normalized to LD2_0 sample (comparator). (B) Normalized 18s rRNA (ng) in respect to host β -actin (ng). _# denotes specific sample replicate. Each sample was measured in triplicate. Standard error of the sample mean is presented. Steroid model, S; Chemotherapeutic model, L; Day 2, D2; Day 3, D3.











g

h





Supplementary Figure S2. Standardized cummeRbund output for global statistics and quality control of RNA-Seq data. (a) Dispersion parameter plotted against counts = fragments per kilobase of transcript per million mapped reads (FPKM) for each gene in a given model. (b) squared coefficient of variation plotted against log_{10} FPKM for each model. Density plot of log_{10} FPKM for all genes in a (c) given model and (d) samples replicates. (e) Box plot of FPKM distributions for a given model and (f) sample replicates. (g) volcano plot of log_2 fold change versus significance ($-log_{10}$ (p-value)). Multidimensional scaling (MDS) plot for gene-level features for (h) each model and (i) sample replicates. Principal component analysis (PCA) plot for gene-level features for (j) each model and (k) sample replicates. Steroid Model, S. Chemotherapeutic Model, L. Day 2, D2. Day 3, D3.





Supplementary Figure S3. Histogram distribution of the number of (a) mouse and (b) *A. fumigatus* genes within a given range of transcript expression for the chemotherapeutic and steroid models of invasive pulmonary aspergillosis on day 2 and 3 post inoculation. (a) mouse gene expression is presented in fragments per kilobase million (FPKM). (b) *A. fumigatus* gene expression is presented in normalized counts. A given bin's range is indicated by the x-axis. Steroid Model, S; Chemotherapeutic Model, L; Day 2, D2; Day 3, D3.



Supplementary Figure S4. Enrichment of known and curated protein-protein interaction networks and pathways (Reactome³⁴) by mouse differentially expressed gene groupings identified amongst the chemotherapeutic and steroid models of invasive pulmonary aspergillosis on day 2 and 3 post inoculation. (a) Summary table of network properties: number of genes in grouping, number of genes identified in protein-protein interaction network, number of edges connecting nodes in a identified network, ratio of edges to nodes, and number of modules (peer-reviewed, assembled, and curated protein interaction networks) greater than 2 members identified in a given network. (b) Representative protein interaction network based upon differentially expressed genes enriched in the chemotherapeutic model in comparison to the steroid model on day 3. (c) bar graph of the number of modules of a given size for a given enriched network. (d) Number of enriched pathways (p < 0.001) from curated databases by a given identified network. LD, chemotherapeutic model; SD, steroid model; 2-3, from day 2 to 3; Up, differentially expressed genes increasing in expression; Down, differentially expressed genes decreasing in expression; Enriched, differentially expressed genes of higher transcript expression for the identified model in comparison to the alternate model for a given day; cDEGs Up, differentially expressed genes increasing in expression from day 2 to day 3 in both models; cDEGS Down, differentially expressed genes decreasing in expression from day 2 to day 3 in both models.



Supplementary Figure S5. Gene expression values (FPKM) for a subset of (a) early cytokines, (b) transcription factors, and (c) secondary stage cytokines expressed in the chemotherapeutic and steroid models of invasive pulmonary aspergillosis on day 2 and 3 post inoculation. Secondary x-axis labels are indicative of association with a given T-helper cell response (T_h). T_{reg}, T regulatory helper cell. T_fh, T follicular helper cell. Steroid Model, S; Chemotherapeutic Model, L; Day 2, D2; Day 3, D3. Standard error of the sample mean is presented.



Supplementary Figure S6. Wiring Diagram for modeling of CD4+T cell differentiation. Extracellular immune signaling molecules are denoted by orange circles and located outside of cells, while counterpart receptors are denoted by cream colored hexagons at the cell membrane. Internalized immune signaling molecules are denoted by green circles. Transcription factors are denoted by gray circles, will modified transcription factors are denoted by green rectangles. Directed green edges indicate a positive impact on a reaction, while directed red edges indicate a degree of inhibition on a reaction.

a LD2 to LD3 Up



b LD2 to LD3 Down



c SD2 to SD3 Up



d SD2 to SD3 Down



e LD2 Enriched



f LD3 Enriched



g SD2 Enriched



h SD3 Enriched



Supplementary Figure S7. Overlay of host differentially expressed genes identified during the chemotherapeutic and steroid models of invasive pulmonary aspergillosis onto the KEGG primary metabolic pathway for mice³⁶. The KEGG primary metabolic pathway for mice was overlaid with differentially expressed genes from day 2 to day 3 in the (ab) chemotherapeutic and (cd) steroid model, and statistically enriched genes in the (ef) chemotherapeutic and (gh) steroid model on day 2 and day 3. Differentially expressed genes are colored in black. Chemotherapeutic Model, L; Steroid Model, S; Day 2, D2; Day 3, D3; Up, differentially expressed genes increasing in expression. Down, differentially expressed genes decreasing in expression. Enriched, differentially expressed genes of higher transcript expression for the identified model in comparison to the alternate model for a given day.

Chemotherapeutic Model



b

Steroid Model



C

Chemotherapeutic/ Steroid Model Day 3





Chemotherapeutic Model

е

Steroid Model



Chemotherapeutic/ Steroid Model Day 3







f

g Chemotherapeutic Model



h Steroid Model



i Chemotherapeutic/ Steroid Model Day 3





Supplementary Figure S8. Gene expression changes for metabolic pathways during the chemotherapeutic and steroid models of invasive pulmonary aspergillosis from day 2 to day 3 post inoculation. Gene expression was integrated into mouse KEGG based maps³⁶ for (abc) the citrate acid (TCA) cycle, (def) glycolysis, and (ghi) arginine biosynthesis (urea cycle) using cytoscape³³ and KEGGScape¹²³. Genes are colored based on log₂-fold change from day 2 to day 3 for the chemotherapeutic model (adg), steroid model (beh), and gene expression ratio between the chemotherapeutic model and steroid model on day 3 (cfi). White boxes with 'KO' prefixes are genes not present or identified in the mouse version of these pathways. White boxes with gene names are genes below the threshold for expression (FPKM < 1). (j) gene expression (FPKM) of known arginine transporters during the chemotherapeutic and steroid models of invasive pulmonary aspergillosis on day 2 and 3 post inoculation. Steroid Model, S; Chemotherapeutic Model, L; Day 2, D2; Day 3, D3.



Supplementary Figure S9. RT-qPCR analysis of *A. fumigatus* genes expressed during chemotherapeutic and steroid treatment mouse models of invasive pulmonary aspergillosis on day 2 and 3 post inoculation. Fold change was determined for expressed putative *A. fumigatus* secreted proteins via (a) RT-qPCR analysis and (b) a FPKM based analysis. Fold-change was normalized for RT-qPCR using β -tubulin and TefA, and presented in relation to LD2 gene expression (comparator) using the $\Delta\Delta CT$ method. For FPKM based analysis data is presented in relation to LD2 gene expression (comparator). Steroid Model, S; Chemotherapeutic Model, L; Day 2, D2; Day 3, D3. Standard error of the sample mean is presented. Note the increased FPKM based fold change for all genes in LD3 and the decreased fold change for all genes in SD2 and SD3 in comparison to the RT-qPCR results.



Supplementary Figure S10. Expression level (normalized counts) for *A. fumigatus* genes associated with the gliotoxin biosynthesis cluster during the chemotherapeutic and steroid models of invasive pulmonary aspergillosis on day 2 and 3 post inoculation. Steroid Model, S; Chemotherapeutic Model, L; Day 2, D2; Day 3, D3. Standard error of the sample mean is presented.